Equities
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)281.00
  • Today's Change0.00 / 0.00%
  • Shares traded5.67k
  • 1 Year change-2.60%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024 14:40 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments8866321,013
Total Receivables, Net153129149
Total Inventory505736
Prepaid expenses7.112214
Other current assets, total------
Total current assets1,0978401,212
Property, plant & equipment, net1048553
Goodwill, net------
Intangibles, net------
Long term investments487476
Note receivable - long term------
Other long term assets151622
Total assets1,2801,0291,373
LIABILITIES
Accounts payable367141
Accrued expenses255246194
Notes payable/short-term debt3100
Current portion long-term debt/capital leases3.93027
Other current liabilities, total773750
Total current liabilities403354312
Total long term debt51237.16
Total debt862334
Deferred income tax1.482.712.77
Minority interest132753
Other liabilities, total811312
Total liabilities549419386
SHAREHOLDERS EQUITY
Common stock878686
Additional paid-in capital1,5221,4971,505
Retained earnings (accumulated deficit)(871)(971)(610)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(8.16)(1.9)5.57
Total equity731610987
Total liabilities & shareholders' equity1,2801,0291,373
Total common shares outstanding871865865
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.